法国类风湿关节炎初始治疗中依那西普和阿达木单抗生物类似药处方的变化：来自ART-SFR注册研究的数据 - Suppr | 超能文献

相似文献

1

Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry.法国类风湿关节炎初始治疗中依那西普和阿达木单抗生物类似药处方的变化：来自ART-SFR注册研究的数据

Joint Bone Spine. 2022 May;89(3):105310. doi: 10.1016/j.jbspin.2021.105310. Epub 2021 Nov 25.

2

Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.皮下注射英夫利昔单抗与阿达木单抗、依那西普和静脉注射英夫利昔单抗治疗类风湿关节炎患者的疗效和安全性：系统文献回顾和荟萃分析。

Expert Rev Clin Immunol. 2021 Jan;17(1):85-99. doi: 10.1080/1744666X.2020.1858803. Epub 2020 Dec 28.

3

Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.在类风湿关节炎和银屑病试验中，原研 TNF 抑制剂和生物类似药的疗效和安全性结局：系统文献回顾。

BioDrugs. 2018 Jun;32(3):193-199. doi: 10.1007/s40259-018-0283-4.

4

Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.阿达木单抗、依那西普和英夫利昔单抗作为类风湿关节炎患者一线生物治疗药物在日常临床实践中的留存率——奥弗涅地区的经验

Int J Rheum Dis. 2018 Nov;21(11):1924-1932. doi: 10.1111/1756-185X.13156. Epub 2017 Sep 13.

5

Direct Comparative Effectiveness Among 3 Anti-Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis.类风湿关节炎真实队列中3种抗肿瘤坏死因子生物制剂的直接比较疗效

J Clin Rheumatol. 2016 Mar;22(2):57-62. doi: 10.1097/RHU.0000000000000358.

6

Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry.英夫利昔单抗、依那西普和阿达木单抗在类风湿关节炎患者中的真实世界成本效益：CREATE注册研究结果

Rheumatol Int. 2016 Feb;36(2):231-41. doi: 10.1007/s00296-015-3374-2.

7

Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).在法国奥弗涅地区的日常临床实践中，阿达木单抗、依那西普和英夫利昔单抗作为脊柱关节炎患者一线或二线生物疗法的保留率。

Int J Rheum Dis. 2018 Nov;21(11):1986-1992. doi: 10.1111/1756-185X.13375. Epub 2018 Aug 30.

8

Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.开始使用生物类似药英夫利昔单抗的类风湿关节炎患者的特征与结局

Rheumatol Int. 2017 Jun;37(6):1007-1014. doi: 10.1007/s00296-017-3663-z. Epub 2017 Feb 18.

9

Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance.对接受TNF-α抑制剂治疗的长期类风湿性关节炎患者进行48个月的疾病活动监测：临床结果预测时机以及生物类似药与原研生物药的疗效比较

Clin Drug Investig. 2024 Mar;44(3):141-148. doi: 10.1007/s40261-024-01341-7. Epub 2024 Jan 31.

10

Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study.类风湿关节炎、强直性脊柱炎和银屑病关节炎中三种肿瘤坏死因子α拮抗剂（阿达木单抗、英夫利昔单抗、依那西普）持续用药率的比较：一项为期10年的回顾性研究。

Joint Bone Spine. 2016 Oct;83(5):607-9. doi: 10.1016/j.jbspin.2016.01.005. Epub 2016 Feb 23.

引用本文的文献

1

Association of Tumor Necrosis Factor Inhibitors with the Risk of Nontuberculous Mycobacterial Infection in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study.肿瘤坏死因子抑制剂与类风湿关节炎患者非结核分枝杆菌感染风险的关联：一项全国性队列研究

J Clin Med. 2023 Nov 9;12(22):6998. doi: 10.3390/jcm12226998.

2

Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study.与原研药相比，阿达木单抗和依那西普生物类似药的差异保留率：一项法国多中心回顾性研究的结果。

Front Med (Lausanne). 2022 Oct 6;9:989514. doi: 10.3389/fmed.2022.989514. eCollection 2022.